A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

Principal Investigator:

Guillermo Garcia-Manero

Treatment Agent:

Azacitidine; Decitabine; Pracinostat

Study Status:

Closed

Study Description:

The goal of this clinical research study is to learn if adding pracinostat to
the drug that you have already received (azacitidine or decitabine) can help to
control MDS. The safety of this drug combination will also be studied.